Flagship blends three biotech startups to form Etcelera

Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.

Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.

Read the full story at Biopharma dive →